Leorah Freeman, MD, PhD

Disability in MS accrues through two distinct biological engines. Recognizing relapse-independent progression changes how clinicians assess patients and how they build trust with those who feel worse despite stable MRI.

MS prevalence continues to rise and the demographic profile is broader than long assumed. The panel identifies progressive biology as the largest remaining unmet need in the disease.